Oncogene-induced replicative stress activates an Atr- and Chk1-dependent response, which has been proposed to be widespread in tumors. We explored whether the presence of replicative stress could be exploited for the selective elimination of cancer cells. To this end, we evaluated the impact of targeting the replicative stress-response on cancer development. In mice (Mus musculus), the reduced levels of Atr found on a mouse model of the Atr-Seckel syndrome completely prevented the development of Myc-induced lymphomas or pancreatic tumors, both of which showed abundant levels of replicative stress. Moreover, Chk1 inhibitors were highly effective in killing Myc-driven lymphomas. By contrast, pancreatic adenocarcinomas initiated by K-Ras G12V showed no detectable evidence of replicative stress and were nonresponsive to this therapy. Besides its impact on cancer, Myc overexpression aggravated the phenotypes of Atr-Seckel mice, revealing that oncogenes can modulate the severity of replicative stress-associated diseases. a r t i c l e s of histone γH2ax (Supplementary Fig. 1 ). This generalized synthetic lethal interaction between Myc and Atr during embryogenesis was unexpected given that Myc overexpression was thought to be restricted to B cells in the Eµ-myc model. However, we found widespread overexpression of Myc in transgenic tissues, which could account for the systemic effects of Eµ-myc on Atr-Seckel development ( Supplementary Fig. 2 ).
Atr hypomorphism prevents Myc-induced lymphomas
We then explored whether the increased levels of Myc had any effect on born Atr S/S mice. The presence of the Myc transgene led to a further 40% reduction in the median lifespan of Atr-Seckel mice (Fig. 1b) . Notably, even though around half of Atr S/S ; Eµ-myc + animals die at about the same age at which Atr +/+ ; Eµ-myc + mice do, we never observed a lymphoma on Eµ-myc + mice that were hypomorphic for Atr (n = 0/24). Moreover, the reduction in Atr levels prevented the pretumoral expansion of the white blood cell compartment that occurs on young Eµ-myc + mice, suggesting that low levels of Atr prevent even the earliest steps of transformation initiated by Myc (Fig. 1c) . To further force lymphomagenesis, we introduced p53 haploinsufficiency 20 into the crosses. In this context, every Eµ-myc + ; p53 +/− mouse invariably developed a full-blown lymphoma at 5 weeks of age (n = 16/16). By contrast, we never observed a lymphoma on the few Atr S/S ; Eµ-myc + ; p53 +/− animals that were born (n = 0/5) (Fig. 1d) . Altogether, these data show that low levels of Atr prevent the development of B-cell lymphomas initiated by Myc. However, Eµ-myc aggravated the phenotypes of Atr-Seckel mice such as microcephaly, micrognathia, pancytopenia or kyphosis (Fig. 2 and data not shown) , explaining the reduced lifespan of Atr S/S ; Eµ-myc + mice.
Atr and Chk1 limit Myc-induced replicative stress and apoptosis
To determine the mechanism of this synthetic lethal interaction between Myc and Atr, we evaluated the impact of targeting the RSR on Myc-induced apoptosis. Addition of 4-hydroxytamoxifen (4-OHT) in MycER-infected mouse embryonic fibroblasts (MEFs) led to an activated DDR 21 , as indicated by the presence of cells presenting high levels of pan-nuclear γH2ax (Fig. 3a,b) . As previously shown, this staining pattern is reflective of replicative stress, because it is restricted to S-phase cells and can also be observed for replication protein A (Rpa) [22] [23] [24] . Accordingly, 24 h of MycER activation led to an accumulation of cells in G2 and the appearance of Rpa foci ( Fig. 3c and Supplementary  Fig. 3 ), both of which would be consistent with an accumulation of replicative stress. At 48 h, MycER-induced apoptosis coincided with a concomitant loss of cells in the S and G2 phases of the cell cycle, suggesting that a fraction of Myc-induced cell death could be coming from cells suffering from replicative stress (Fig. 2c) . Atr S/S MEFs showed increased levels of Myc-induced γH2ax and were highly sensitive to Myc-induced apoptosis (Fig. 3b,c) . Likewise, Atr 24 or Chk1 inhibitors also sensitized cells to MycER-induced apoptosis ( Supplementary  Fig. 4) . Notably, this synthetic lethal effect was even more pronounced in p53-deficient cells, which was again associated with higher levels of Myc-induced γH2ax (Supplementary Fig. 5 ). We made similar observations with MEFs from a strain in which MycER was knocked-in at the ROSA26 locus 25 (Supplementary Fig. 6 ). The data above show that cells harboring Myc are particularly sensitive to RSR inhibitors through an apoptotic mechanism that is independent of p53.
Therapeutic effect of Chk1 inhibitors on Myc-induced lymphomas
The mouse data presented above revealed that, in vivo, reduced Atr levels prevent the development of Myc-induced lymphomas. However, a b 5-month-old mice of the indicated genotypes were calculated from computerized tomography analysis of the crania (n = 6, **P < 0.01, ***P < 0.001).
(e,f) Platelet (e) and red blood cell (RBC) (f) counts from 2-month-old mice without detectable lymphoma (n = 5). Error bars, s.d. a r t i c l e s preventing tumor development does not imply that such a strategy will work for tumor treatment. We thus tested the effect of inhibiting the RSR in a cohort of mice bearing isogenic tumors by transplanting cells from Eµ-myc + lymphomas 26 . When tumors became palpable, we injected recipient mice intraperitoneally with two independent Chk1 inhibitors and assessed the effect of the drugs after 16 h. Consistent with the oncogene-induced DDR model [6] [7] [8] , Myc-induced lymphomas presented numerous cells with a pan-nuclear staining of γH2ax (Fig. 4a) . Treatment with Chk1 inhibitors promoted a strong increase of γH2ax and apoptosis throughout the lymphoma, at doses at which little apoptosis was elicited on a healthy spleen (Fig. 4a,b and Supplementary  Fig. 7) . We also observed the same effect of Chk1 inhibitors on p53-deficient Eµ-myc + lymphomas (data not shown). In agreement with these data, 9 d of therapy with UCN-01 led to a regression of Mycinduced lymphomas under every measurable parameter, including spleen and lymph node size, and the levels of circulating leukocytes in the bloodstream (Fig. 4c,d) . Moreover, the efficacy of this approach is not restricted to mice, as Chk1 inhibitors were also toxic for human Burkitt lymphoma lines, the sensitivity being maximal on the lymphomas showing the highest levels of Myc (Supplementary Fig. 8a,b) . The acute response of human Burkitt lymphomas to Chk1 inhibitors was kept in the context of a preclinical model of subcutaneous xenografts (Supplementary Fig. 8c-e) . Likewise, knockdown of Chk1 in human primary foreskin (BJ) cells increased their sensitivity toward MycERinduced apoptosis (Supplementary Fig. 8f,g ). In summary, targeting the RSR elicits a robust synthetic-lethal interaction in Myc-induced lymphomas, which can be exploited for the pharmacological treatment of these tumors even in the absence of a proficient p53 response.
Targeting the RSR in Myc- and Ras-driven tumors
Last, we explored the extent to which this therapy was extensible to other tumors. As we recently reported for Atr inhibitors 24 , the selective toxicity of Chk1 inhibitors was not restricted to Myc and could also be observed with other replicative stress-generating oncogenes such as cyclin E1 (refs. 7,27; Supplementary Fig. 9 ). By contrast, introduction of an oncogenic allele of K-Ras (K-Ras G12V ) in its endogenous locus did not yield any detectable increase in replicative stress, and cells harboring this oncogene were not particularly sensitive to Chk1 inhibitors (Supplementary Fig. 9 ). It is important to note that although overexpression of the Ras oncogene with retroviral plasmids does generate Atr-restricted DNA damage 28 , this in vitro model does not fully recapitulate the way by which Ras induces tumors. In contrast to Myc, Ras does not need to be overexpressed, and mutation of Ras in its endogenous locus is sufficient to promote malignant transformation 29, 30 . To validate these observations in vivo, we compared the efficacy of Chk1 inhibitors in two independent models of pancreatic cancer driven by Myc 31 or Ras 32 oncogenes. Similar to Myc-induced lymphomas, pancreatic tumors from transgenic mice in which the expression of myc is driven by the elastase-1 promoter (Ela-myc) presented a high frequency of cells with a pan-nuclear γH2ax staining (Fig. 5a) . By contrast, and as previously shown for K-Ras G12V -induced lung tumors 33, 34 , pancreatic adenocarcinomas obtained through the introduction of an oncogenic K-Ras G12V allele did not show any evidence of an activated DDR (Fig. 5b) . Moreover, although treatment a r t i c l e s with Chk1 inhibitors increased the levels of γH2ax and apoptosis in Myc-induced pancreatic tumors, it did not have any detectable impact on those induced by Ras (Fig. 5a-c) . Notably, induction of γH2ax and apoptosis by Chk1 inhibitors in the Ela-myc model was restricted to the Myc-overexpressing tumor and was not detected in the neighboring tissues, providing a good example of the synthetic-lethal nature of this approach (Fig. 5d) . In contrast to the lymphomas, in the case of Ela-myc pancreatic adenocarcinomas, the effect of Chk1 inhibitors was not curative, and animals died regardless of the treatment. One possible explanation is that this result is linked to the poor drug delivery to the tumor, which is known to be a major limitation for the treatment of pancreatic cancer 35 . To overcome this constraint, we introduced the Ela-myc transgene on an Atr-Seckel background, so that a limited RSR would be present constitutively in the pancreas. Notably, and in contrast to the lymphoid system, the pancreases of Atr-Seckel mice showed no apparent pathologies. However, in contrast to Atr +/+ ; Ela-myc + mice, which at 16 weeks of age carry several pancreatic ductal adenocarcinomas (PDAs) (n = 25/25), none of the Atr S/S ; Eµ-myc + mice showed detectable tumors (n = 0/4) (Supplementary Fig. 10) . Although an effective treatment might still demand coadjuvant therapies that facilitate drug delivery, these data reinforce the notion that targeting the RSR might be particularly useful in the context of tumors with high levels of replicative stress.
DISCUSSION
The data presented here are consistent with the oncogene-induced DDR model, in which Atm would limit tumorigenesis through the activation of p53. Accordingly, Atm has been shown to mediate the induction of p53-dependent apoptosis in Eµ-myc lymphomas 16, 17 . However, because persistent replicative stress leads to chromosomal breaks 36 , a break-Atm-p53-dependent and a replicative stressAtr-p53-independent apoptotic response would coexist in tumors. In fact, Myc-induced lymphomas show both Atm and Chk1 phosphorylation 15 , and MycER expressing MEFs also show evidence of Atm and Atr activation (Supplementary Fig. 11a ). Our work reveals that targeting Atr or Chk1 can specifically exploit the replicative stress-p53-independent apoptotic branch; thus, this can become an effective therapy for the treatment of tumors showing high levels of replicative stress (Supplementary Fig. 11b) . We should note that this strategy is based on the fact that the presence of replicative stress sensitizes cells to RSR inhibitors, and it is therefore not exclusive for Chk1 and Myc. In line with this, neuroblastomas driven by MYC(N) have also been shown to be sensitive to Chk1 inhibition 37 , and the same synthetic-lethal interaction can also be seen with Atr inhibitors and other replicative stress-inducing oncogenes such as cyclin E1 (ref. 38) . Whereas it is likely that not all tumors show the same levels of replicative stress, this could easily be assessed in tumor biopsies and could therefore be used as a predictable biomarker of the effectiveness of Atr or Chk1 inhibitors.
We are aware that the efficacy of Chk1 inhibitors in the clinic has been modest. However, the same effect might have been observed if imatinib or olaparib had been tested as general anticancer strategies regardless of whether the tumors were carrying ABL 39 or BRCA 40 mutations, respectively. The benefit of finding a synthetic-lethal interaction is that it allows optimizing the efficacy of a therapy by restricting its use to those tumors that are most likely to respond 41 . The use of chemical inhibitors of the response to reactive oxygen species (ROS) to target cancer cells with elevated ROS levels has recently provided an example of these ideas 5 . In this context, we hope that the synthetic-lethal interaction described here can be incorporated into the rationale of clinical trials using Atr or Chk1 inhibitors. We believe that these drugs would be mostly useful for the treatment of human cancers with high levels of replicative stress, even more so by focusing on those cases in which p53 is mutated and classical genotoxic chemotherapy has ceased to work.
With regards to Myc, our data reinforce the emerging role of this oncogene in regulating replication under conditions of stress 42 . Myc can promote entry into S phase by stimulating cyclin E-Cdk2 and E2f1 activity 43 , or by directly stimulating replication 44 . Consistent with this, we detected higher DNA synthesis rates in OHT-treated MycER MEFs (Supplementary Fig. 6b) . However, several lines of evidence suggest that the increased S-phase entry driven by Myc might be prone to replicative stress 45, 46 . Additionally, Myc can also limit Atr signaling by directly affecting the stability of the checkpoint protein Topbp1 (ref. 47) . Notably, part of the Myc transcriptional response is dedicated to limiting replicative stress, either by promoting the biosynthesis of nucleotides 48 or by limiting the Atm-dependent DDR 49 . Thus, among the different oncogenes, Myc might be particularly prone to generate replicative stress.
Last, previous work showed that Myc-induced replicative stress was limited by Wrn, an helicase mutated in the progeroid Werner syndrome 46 . The fact that Myc increased genomic instability on Werner syndrome cells suggested that certain cancer-associated mutations could aggravate the phenotypes of progeroid diseases. Our data on Atr-Seckel; Eµ-myc mice provide in vivo proof of this concept and show that oncogenes can contribute to the severity of replicative stress-driven syndromes. 
